Endothelial dysfunction in diabetes
Open accessThe DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Endothelial dysfunction plays a key role in the pathogenesis of diabetic vascular disease. The endothelium controls the tone of the underlying vascular smooth muscle through the production of vasodilator mediators. The endothelium‐derived relaxing factors (EDRF) comprise nitric oxide (NO), prostacyclin, and a still elusive endothelium‐derived hyperpolarizing factor (EDHF). Impaired endothelium‐dependent vasodilation has been demonstrated in various vascular beds of different animal models of diabetes and in humans with type 1 and 2 diabetes. Several mechanisms of endothelial dysfunction have been reported, including impaired signal transduction or substrate availibility, impaired release of EDRF, increased destruction of EDRF, enhanced release of endothelium‐derived constricting factors and decreased sensitivity of the vascular smooth muscle to EDRF. The principal mediators of hyperglycaemia‐induced endothelial dysfunction may be activation of protein kinase C, increased activity of the polyol pathway, non‐enzymatic glycation and oxidative stress. Correction of these pathways, as well as administration of ACE inhibitors and folate, has been shown to improve endothelium‐dependent vasodilation in diabetes. Since the mechanisms of endothelial dysfunction appear to differ according to the diabetic model and the vascular bed under study, it is important to select clinically relevant models for future research of endothelial dysfunction. British Journal of Pharmacology (2000) 130 , 963–974; doi: 10.1038/sj.bjp.0703393
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both hyperglycemia and hyperinsulinemia alter the endothelium,27 disrupting the normal atheroprotective nitric oxide regulatory environment and encouraging a generalized proinflammatory, vasoconstrictive state predisposing to atherothrombosis.27–29”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Impaired endothelium-dependent vasodilation has been demonstrated in various vascular beds of animal models of diabetes and humans with type 1 and type 2 diabetes (80).”
From Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities (2010) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441 · cited 1×
“Although AGE formation occurs during the normal ageing process, it is markedly accelerated during diabetes, as a consequence of an increase in substrate, e.g. glucose, and in the prevailing oxidant stress in this disease (Baynes & Thorpe, 1999).”
BackgroundEndothelium‐derived relaxing and contracting factors
Furchgott, R. F., & Vanhoutte, P. M. (1989) · The FASEB Journal · doi:10.1096/fasebj.3.9.2545495 · Cited by 1,993
Self-citationOxidative Stress and Diabetic Vascular Complications
Giugliano, D., Ceriello, A., & Paolisso, G. (1996) · Diabetes Care · doi:10.2337/diacare.19.3.257 · Cited by 1,930
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Protein kinase C activation and the development of diabetic complications.
Koya, D., & King, G. L. (1998) · Diabetes · doi:10.2337/diabetes.47.6.859 · Cited by 1,330
Yan, S. D., Schmidt, A. M., Anderson, G. M., Zhang, J., Brett, J., Zou, Y. S., Pinsky, D., & Stern, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36966-1 · Cited by 1,306
Wolff, S. P., & Dean, R. T. (1987) · Biochemical Journal · doi:10.1042/bj2450243 · Cited by 1,271
Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor
Rubanyi, G. M., & Vanhoutte, P. M. (1986) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1986.250.5.h822 · Cited by 1,188
Self-citationBucala, R., Tracey, K. J., & Cerami, A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115014 · Cited by 1,165
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Johnstone, M. T., Creager, S. J., Scales, K. M., Cusco, J. A., Lee, B. K., & Creager, M. A. (1993) · Circulation · doi:10.1161/01.cir.88.6.2510 · Cited by 1,124
Research works printed but not linked: 6
- DE VRIESE A., 1999, Impaired endothelium‐derived hyperpolarizing factormediated renal vasodilatory response in diabetes: restoration with folate, J. Am. Soc. Nephrol., 10, 394A
- FRIEDMAN E.A., 1999, Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications, Diabetes Care, 22, B65
- FULTON D., 1996, Cytochrome P450 arachidonate metabolites: deficit in diabetes mellitus, FASEB J., 9, A113
- QUILLEY J., 1996, NO‐independent coronary vasodilation to bradykinin in diabetes, Hypertension, 28, P178
- 10.2337/diabetes.42.9.1246 · doi:10.2337/diabetes.42.9.1246
- 10.1042/cs19980382 · doi:10.1042/cs19980382
Cited by
Items 501–600 of 1,000
Shin, W., Cuong, T. D., Lee, J. H., Min, B., Jeon, B. H., Lim, H. K., & Ryoo, S. (2011) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2011.15.3.123 · Cited by 31
“creased NO production, and has been demonstrated to contribute to endothelial dysfunction, in a number of diseases/ pathophysiological processes, including aging [4], diabetes [15-17], hypertension [18-20], and atherosclerosis [14,21].”
BackgroundFerreira, N. S., Cáu, S. B. D. A., Silva, M. A. B., Manzato, C. P., Mestriner, F., Matsumoto, T., Carneiro, F. S., & Tostes, R. C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00034 · Cited by 31
“ORIGINAL RESEARCH ARTICLE published: 02 March 2015 doi: 10.3389/fphar.2015.00034 Diabetes impairs the vascular effects of aldosterone mediated by G protein-coupled estrogen receptor activation”
BackgroundInfluentialAssessment of erectile dysfunction in diabetic patients
Hamdan, F. B., & Al‐Matubsi, H. Y. (2008) · International Journal of Andrology · doi:10.1111/j.1365-2605.2008.00873.x · Cited by 31
“…end product, compounds that are formed as a result of non-enzymatic reaction between glucose and the amino groups of proteins (Dyck et al., 1999; De Vriese et al., 2000) which promote vascular disease and result in reduced endoneurial blood flow and nerve hypoxia with altered nerve function and…”
Pieper, G. M., & Siebeneich, W. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00508-2 · Cited by 31
Endothelial arginase II and atherosclerosis
Ryoo, S., Berkowitz, D. E., & Lim, H. K. (2011) · Korean Journal of Anesthesiology · doi:10.4097/kjae.2011.61.1.3 · Cited by 30
“Alternations in NO signaling have been shown in both animal models and human subjects with hypertension [26], diabetes [27], hypercholesterolemia [28,29], heart failure [29] and atherosclerosis [30].”
BackgroundLoss of bone morphogenetic protein-binding endothelial regulator causes insulin resistance
Mao, H., Li, L., Fan, Q., Angelini, A., Saha, P. K., Wu, H., Ballantyne, C. M., Hartig, S. M., Xie, L., & Pi, X. (2021) · Nature Communications · doi:10.1038/s41467-021-22130-2 · Cited by 30
Matsumoto, T., Ishida, K., Taguchi, K., Kobayashi, T., & Kamata, K. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09308fp · Cited by 30
Involvement of Rho-kinase in experimental vascular endothelial dysfunction
Shah, D. I., & Singh, M. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-2679-6 · Cited by 30
“Vascular endothelial dysfunction has been implicated in secondary complications due to essential hypertension [1], congestive heart failure [2], diabetes mellitus [ 3 ], atherosclerosis [4], and hyperhomocysteinemia [5].”
BackgroundInfluentialMori, A., Saigo, O., Hanada, M., Nakahara, T., & Ishii, K. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08320fp · Cited by 30
Yönem, A., Duran, C., Ünal, M., İpçioğlu, O. M., & Özcan, Ö. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.03.001 · Cited by 30
Obesity, Insulin Resistance and Hepatic Perfusion
Brock, R. W., & Dorman, R. B. (2007) · Microcirculation · doi:10.1080/10739680701282986 · Cited by 30
“Regardless, the impact of oxidants on hepatic microvascular abnormalities include impaired signal transduction pathways or substrate availability, impaired release or increased metabolism of vasodilatory mediators, and decreased reactivity of the contractile machinery to vasoactive mediators [16].”
BackgroundSauvé, M., Hui, S., Dinh, D. D., Foltz, W. D., Momen, A., Nedospasov, S. A., Offermanns, S., Husain, M., Kroetsch, J. T., Lidington, D., et al. (2016) · Diabetes · doi:10.2337/db15-1450 · Cited by 30
“Many studies conclude that endothelial dysfunction, a broad range of abnormalities that disrupts the delicate balance between dilatory (most notably nitric oxide [35]) and constrictive mediators (36), is the mechanistic basis of enhanced microvascular contractility in diabetes (37,38).”
BackgroundBoon, E. A. J., Croft, K. D., Shinde, S., Hodgson, J. M., & Ward, N. C. (2017) · Food & Function · doi:10.1039/c7fo00926g · Cited by 30
Nano-mechanical model of endothelial dysfunction for AFM-based diagnostics at the cellular level
Szymoński, M., Targosz‐Korecka, M., & Malek-Zietek, K. E. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.05.003 · Cited by 30
Uncontrolled type 1 diabetes mellitus and endothelial dysfunction in adolescents.
Shachor‐Meyouhas, Y., Pillar, G., & Shehadeh, N. (2007) · PubMed · Cited by 30
Alabadí, J. A., Miranda, F. J., Lloréns, S., Centeno, J. M., Marrachelli, V. G., & Alborch, E. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.01.005 · Cited by 30
“Nevertheless, it still remains a task to elucidate the mechanisms by which the impaired endothelial regulation produces an abnormal vascular reactivity in diabetes (De Vriese et al., 2000).”
BackgroundVallejo, M., Angulo, S., García-Martínez, D., García, A., & Barbas, C. (2008) · Journal of Chromatography A · doi:10.1016/j.chroma.2008.02.024 · Cited by 30
Cruz, J. P. D. L., Guerrero, A., Paniego, M., Arranz, I., Moreno, A., & Cuesta, F. (2002) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-001-0507-9 · Cited by 30
Triggle, C. R., Howarth, A. G., Cheng, Z. J., & Ding, H. (2005) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y05-069 · Cited by 30
“…have all been suggested to contribute to the development of ED and vascular pathologies (Cosentino and Lüscher 1998; Creager et al. 2003; De Vriese et al. 2000; Pannirselvam et al. 2003) with the majority view that ED and vascular disease occur secondarily to the development of insulin…”
BackgroundSurgery Is Preferred for the Diabetic With Multivessel Disease
King, S. B. (2005) · Circulation · doi:10.1161/circulationaha.104.483339 · Cited by 30
Kant, S., Sellke, F. W., & Feng, J. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151208 · Cited by 29
Ma, Y., Deng, Y., Li, N., Dong, A., Li, H., Chen, S., Zhang, S., & Zhang, M. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115768 · Cited by 29
Four Pathways Involving Innate Immunity in the Pathogenesis of Preeclampsia
Bounds, K. R., Newell‐Rogers, M. K., & Mitchell, B. M. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00020 · Cited by 30
Endothelin-1 Regulation Is Entangled in a Complex Web of Epigenetic Mechanisms in Diabetes
Biswas, S., Feng, B., THOMAS, A., CHEN, S., Aref‐Eshghi, E., Sadiković, B., & Chakrabarti, S. (2018) · Physiological Research · doi:10.33549/physiolres.933836 · Cited by 29
Khan, F. A., Al‐Jameil, N., Arjumand, S., Khan, M. F., Tabassum, H., Alenzi, N., Hijazy, S. M., Alenzi, S., Subaie, S., & Fatima, S. (2015) · Biological Trace Element Research · doi:10.1007/s12011-015-0379-3 · Cited by 29
Chen, X., Feng, L., & Jin, H. (2013) · BMC Cell Biology · doi:10.1186/1471-2121-14-22 · Cited by 29
“Hyperglycemia plays an important role in the etiology of endothelial dysfunction [26,31].”
BackgroundBaluchnejadmojarad, T., Roghani, M., & Khastehkhodaie, Z. (2009) · Phytotherapy Research · doi:10.1002/ptr.3078 · Cited by 29
“In addition, endothelium-dependent vasodilatation is impaired in diabetic vascular beds (De Vriese et al., 2000) as a result of free radicals (Cameron et al., 1998).”
Cheng, Z. J., Jiang, Y., Ding, H., Severson, D. L., & Triggle, C. R. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y07-010 · Cited by 29
Endothelium-specific gene and stem cell-based therapy for erectile dysfunction
Strong, T. D., Gebska, M. A., Burnett, A. L. “., Champion, H. C., & Bivalacqua, T. J. (2008) · Asian Journal of Andrology · doi:10.1111/j.1745-7262.2008.00362.x · Cited by 29
Sharma, S., Singh, M., & Sharma, P. L. (2012) · PubMed · Cited by 29
Gestational Diabetes - Causes, Diagnosis and Treatment
Sobrevía, L. (2013) · InTech eBooks · doi:10.5772/46133 · Cited by 29
Carrasco, O. F., Ranero, A., Hong, E., & Vidrio, H. (2009) · Angiology · doi:10.1177/0003319709332108 · Cited by 29
Enhancement of Endothelial Function by Pregnancy
Ramsay, J. E., Simms, R., Ferrell, W. R., Crawford, L., Greer, I. A., Lumsden, M. A., & Sattar, N. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.2.475 · Cited by 29
“These molecules quench NO and, in combination with free radicals such as superoxide anions, which directly inactivate NO, are responsible for reducing the bioavailability of NO (8).”
BackgroundYin, Q., Fu, S., He, P., & Xiong, Y. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.02.003 · Cited by 29
“Endothelial dysfunction, characterized by impaired nitric oxide (NO)-mediated endotheliumdependent vasodilatation, is a common pathogenesis in the development of diabetic vascular diseases [3,4].”
BackgroundVascular reactivity and thiazolidinediones
Dandona, P., Aljada, A., & Chaudhuri, A. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.015 · Cited by 29
Diabetes mellitus: an important risk factor for peripheral vascular disease
Giannopoulos, S., & Armstrong, E. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1736562 · Cited by 29
9-Hydroxycanthin-6-One Induces Penile Erection and Delays Ejaculation
Chiou, W.-F., & Wu, T.-S. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02296.x · Cited by 28
Bressler, J., Pankow, J. S., Coresh, J., & Boerwinkle, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079466 · Cited by 28
Banumathi, E., Sheikpranbabu, S., Haribalaganesh, R., & Gurunathan, S. (2009) · Experimental Eye Research · doi:10.1016/j.exer.2009.09.014 · Cited by 28
RetractedCruz, J. P. D. L., Río, S. D., Arrebola, M. M., López-Villodres, J. A., Jebrouni, N., & Correa, J. A. G. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.01.017 · Cited by 28
Type 2 Diabetes and Vascular Endothelial Dysfunction
Torimoto, K., Okada, Y., & Tanaka, Y. (2018) · Journal of UOEH · doi:10.7888/juoeh.40.65 · Cited by 28
Zhu, T., Wang, H., Wang, L., Zhong, X., Huang, W., Deng, X., Guo, H., Xiong, J., Xu, Y., & Fan, J. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7378 · Cited by 28
“Endothelial dysfunction initiates vascular pathogenesis and may finally lead to diabetic vasculopathy (7).”
El‐Awady, M. S., El‐Agamy, D. S., Suddek, G. M., & Nader, M. A. (2013) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-013-0299-7 · Cited by 28
“This could be explained by the high glucose-induced impairment of endothelial functions, which plays a key role in the pathogenesis of diabetic vascular disease [9, 11], manifested by dysfunction in both contraction and relaxation.”
BackgroundMoon, M. K., Kang, D. G., Lee, Y. J., Kim, J. S., & Lee, H. S. (2008) · Vascular Pharmacology · doi:10.1016/j.vph.2008.11.007 · Cited by 28
Ding, H., Howarth, A. G., Pannirselvam, M., Anderson, T. J., Severson, D. L., Wiehler, W. B., Triggle, C. R., & Tuana, B. S. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00037.2005 · Cited by 28
“Thus, although the specific role of SLMAP in the regulation of endothelial function remains to be determined, it is well established that caveolae are an essential component of the regulation of eNOS in endothelial cells (25), and a reduction in the bioavailability of endothelium-derived NO is a common feature observe…”
BackgroundThomsen, K., Rubin, I., & Lauritzen, M. (2002) · The Journal of Physiology · doi:10.1113/jphysiol.2002.023564 · Cited by 28
“In STZ-induced diabetes, impaired ACh-induced vasodilatation during NOS and COX inhibition has been found in the renal microcirculation in vivo and in mesenteric arteries in vitro (Fukao et al. 1997; De Vriese et al. 2000a).”
BackgroundCruz, J. P. D. L., Arrebola, M. M., Villalobos, M. A., Pinacho, A., Guerrero, A., Correa, J. A. G., & de la Cuesta, F. S. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.10.055 · Cited by 28
“One of the main biochemical mechanisms involved in this pathogenic process is diminished endothelial and leukocyte synthesis of prostacyclin and nitric oxide (NO) (De Vriese et al., 2000).”
BackgroundResultDavel, A. P., Rossoni, L. V., & Vassallo, D. V. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00679-8 · Cited by 28
Systematic Appraisal Using Immunohistochemistry of Brain Pathology in Aged and Demented Subjects
Aho, L., Parkkinen, L., Pirttilä, T., & Alafuzoff, I. I. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000122963 · Cited by 28
Vascular Endothelial Growth Factor Level in the Serum of Diabetic Patients with Retinopathy
Çavuşoğlu, A. Ç., Bilgili, S., Alaluf, A., Doğan, A., Yılmaz, F., Aslanca, D., Karaca, B., Yüksel, B., & Topaloglu, E. (2007) · Annals of Ophthalmology · doi:10.1007/s12009-007-0037-2 · Cited by 28
“Diabetes leads to the specific microvascular complications retinopathy, nephropathy, and neuropathy which may reflect underlying endothelial dysfunction ( 1 ).”
BackgroundLi, Y., Descorbeth, M., & Anand‐Srivastava, M. B. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.91422.2007 · Cited by 28
Extracellular Vesicles as Mediators of Endothelial Dysfunction in Cardiovascular Diseases
Jimenez‐Trinidad, F. R., Calvo-Gomez, S., Sabaté, M., Brugaletta, S., Campuzano, V., Egea, G., & Dantas, A. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031008 · Cited by 27
“Known risk factors, including an imbalance in oxidative stress, increased blood pressure, hyperglycemia, dyslipidemia, exposure to environmental pollutants, chemical agents, and aging, can contribute to the onset or progression of endothelial dysfunction [10–13].”
Pernomian, L., Gomes, M. S., Restini, C. B. A., Ramalho, L. N. Z., Tirapelli, C. R., & de Oliveira, A. M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.036 · Cited by 27
“One of the early events involved in the pathogenesis of the atherosclerosis triggered by Diabetes is the endothelial dysfunction (Dandona, 2009), characterized by an impairment of the endothelium-dependent vasorelaxation mechanisms (De Vriese et al., 2000).”
BackgroundDelbin, M. A., & Trask, A. J. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.02.021 · Cited by 27
Zhang, C., Abdukerim, M., Abilailieti, M., Tang, L., Ling, Y., & Pan, S. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.07.017 · Cited by 27
Rampin, A., Carrabba, M., Mutoli, M., Eman, C. L., Testa, G., Madeddu, P. R., & Spinetti, G. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0134 · Cited by 28
“This event causes the accumulation of glycolytic metabolites, leading to the activation of numerous metabolic pathways, such as protein kinase C, a known activator of Nrf2, sorbitol, but also methylglyoxal (MG) and AGEs, therefore increasing oxidative stress and apoptosis (35, 64).”
Ishida, K., Matsumoto, T., Taguchi, K., Kamata, K., & Kobayashi, T. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2012.02469.x · Cited by 27
“…indicate that the relaxation responses induced by various agents are abnormally weak in diabetic patients and in animal models of diabetes, such as the streptozotocin (STZ)-induced diabetic rat (Poston & Taylor 1995, De Vriese et al. 2000, Kobayashi et al. 2000, 2005, Matsumoto et al. 2003, 2007).”
BackgroundInfluentialVasodilator Effects of Adrenomedullin on Retinal Arterioles in Streptozotocin-Induced Diabetic Rats
Kaneko, Y., Saito, M., Mori, A., Sakamoto, K., Nakahara, T., & Ishii, K. (2006) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.22.317 · Cited by 27
“21,22 Also in the ocular vasculature, acetylcholine-induced dilator responses were markedly impaired in STZ-induced diabetic rats.”
Javeshghani, D., Schiffrin, E. L., Sairam, M. R., & Touyz, R. M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.07.002 · Cited by 27
Brunetti, N. D., Maulucci, G., Casavecchia, G., Distaso, C., Gennaro, L. D., Pellegrino, P. L., & Biase, M. D. (2007) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2007.00293.x · Cited by 27
Badhwar, S., Chandran, D. S., Jaryal, A. K., Narang, R., & Deepak, K. K. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117748840 · Cited by 27
Metabolic regulation of endothelial SK channels and human coronary microvascular function
Liu, Y., Kabakov, A. Y., Xie, A., Shi, G., Singh, A. K., Sodha, N. R., Ehsan, A., Usheva, A., Agbortoko, V., Koren, G., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.028 · Cited by 27
The vasorelaxant effect of hydrogen sulfide is enhanced in streptozotocin-induced diabetic rats
Denizaltı, M., Bozkurt, T. E., Akpulat, U., Şahin-Erdemli, İ., & Abacıoğlu, N. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0601-6 · Cited by 27
“Another disease state with the potential role of H2S is diabetes mellitus, since this disease is associated with altered synthesis of endogenous mediators that contribute to the impairment of vascular reactivity ( De Vriese et al. 2000 ).”
BackgroundKamata, K., Kobayashi, T., Matsumoto, T., Kanie, N., Oda, S.-I., Kaneda, A., & Sugiura, M. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.267 · Cited by 27
Zhang, D., Gao, X., Wang, Q., Qin, M., Liu, K., Huang, F., & Liu, B. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12017 · Cited by 27
Effect of Fidarestat and α‐Lipoic Acid on Diabetes‐Induced Epineurial Arteriole Vascular Dysfunction
Yorek, M. A., Coppey, L. J., Gellett, J. S., Davidson, E. P., & Lund, D. D. (2003) · Journal of Diabetes Research · doi:10.1080/15438600490277824 · Cited by 27
“Res., 5:123–135, 2004 Copyright c© Taylor and Francis Inc. ISSN: 1543-8600 print / 1543-8619 online DOI: 10.1080/15438600490277824”
InfluentialEffects of clopidogrel and ticlopidine on experimental diabetic ischemic retinopathy in rats
Cruz, J. P. D. L., Arrebola, Correa, J. A. G., Martinez-Cerdán, Moreno, & de la Cuesta, S. F. (2003) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-002-0657-4 · Cited by 27
Papaetis, G. S., Sacharidou, A., Michaelides, I. C., Mikellidis, K. C., & Karvounaris, S. A. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x314035241006185109 · Cited by 26
“Almost every IR state is characterized by a dysfunctional endothelium, which is now considered as the pivotal key event in the evolution of atherosclerosis [206, 207].”
Akther, F., Razan, M. R., Shaligram, S. S., Graham, J. L., Stanhope, K. L., Allen, K. N., Vázquez‐Medina, J. P., Havel, P. J., & Rahimian, R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.616317 · Cited by 26
Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
García‐Vega, D., González‐Juanatey, J. R., & Eirás, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 26
Nevelsteen, I., den Bergh, A. V., der Mieren, G. V., Vanderper, A., Mubagwa, K., Bult, H., & Herijgers, P. (2013) · Journal of Vascular Research · doi:10.1159/000355221 · Cited by 26
Sleem, M., Taye, A., El‐Moselhy, M. A., & Mangoura, S. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.09.032 · Cited by 26
“Conditions contributing to diabetic vascular remodeling and dysfunction include effects of oxidative stress and decreased nitric oxide (NO) bioavailability (De Vriese et al., 2000; Ceriello, 2006).”
BackgroundLin, F., & Gou, X. (2013) · International Journal of Impotence Research · doi:10.1038/ijir.2013.19 · Cited by 26
Red blood cell ATP/ADP & nitric oxide: The best vasodilators in diabetic patients
Bakhtiari, N., Hosseinkhani, S., Larijani, B. A., Mohajeri‐Tehrani, M. R., & Fallah, A. (2012) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-11-9 · Cited by 26
Wang, S., Li, J., Zhang, C., Xu, G., Tang, Z., Zhang, Z., Liu, Y., & Wang, Z. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7437 · Cited by 26
Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?
Yorek, M. A. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210504101609 · Cited by 26
Fenofibrate attenuates nicotine-induced vascular endothelial dysfunction in the rat
Chakkarwar, V. A. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.08.215 · Cited by 26
“Endothelium regulates the vascular tone andmaintains the free flow of blood in the vessel and possesses antiatherogenic, antiplatelet and antiproliferative properties (De Vriese et al., 2000; Balakumar et al., 2009a).”
BackgroundGarcía, M., Morán, A., Martín, M. L., Barthelmebs, M., & Román, L. S. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.03.020 · Cited by 26
C-peptide exerts antithrombotic effects that are repressed by insulin in normal and diabetic mice
Lindenblatt, N., Braun, B., Menger, M. D., Klar, E., & Vollmar, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0152-4 · Cited by 26
“As a consequence, nuclear factor κB is upregulated and the formation of vasoconstrictive prostanoids and endothelins is increased [3, 4].”
BackgroundHan, Y., Li, X., Zhou, S., Meng, G., Xiao, Y., Zhang, W., Wang, Z., Xie, L., Liu, Z., Lu, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050402 · Cited by 26
“It is important to note that STZ-induced diabetes mellitus has been confirmed to produce experimental vascular endothelial dysfunction [13].”
BackgroundGreenstein, A. S., Price, A. H., Sonoyama, K., Paisley, A. N., Khavandi, K., Withers, S., Shaw, L., Paniagua, O. A., Malik, R. A., & Heagerty, A. M. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.129718 · Cited by 26
Review: Endothelial dysfunction in type 2 diabetes
Storey, A. M., Perry, C., & Petrie, J. R. (2001) · The British Journal of Diabetes · doi:10.1177/14746514010010010401 · Cited by 26
Trippe, B. S., Barrentine, L. W., Curole, M. V., & Tipa, E. V. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103215 · Cited by 26
Ghibu, S., Richard, C., Delemasure, S., Vergely, C., Mogoșan, C., & Mureșan, A. (2008) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2008.02.018 · Cited by 26
Nivoit, P., Wiernsperger, N. F., Moulin, P., Lagarde, M., & Renaudin, C. (2003) · Diabetologia · doi:10.1007/s00125-003-1225-2 · Cited by 26
“In diabetes, endothelial dysfunction is considered as a critical and initiating factor in the development of chronic diabetic macro- and microvascular disease and it becomes a great challenge to understand its mechanisms and aetiology [43].”
BackgroundCampolo, J., Penco, S., Bianchi, E., Colombo, L., Parolini, M., Caruso, R., Sedda, V., Patrosso, M. C., Cighetti, G., Marocchi, A., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.029 · Cited by 26
Pharmacological Interventions to Prevent Vascular Endothelial Dysfunction: Future Directions
Balakumar, P., Koladiya, R. U., Ramasamy, S., Rathinavel, A., & Singh, M. (2008) · Eisei kagaku · doi:10.1248/jhs.54.1 · Cited by 26
The Vasculature in Diabetic Nephropathy: All Tied Up?
Maski, M. R., & Parikh, S. M. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013090966 · Cited by 26
Mokhtar, S. S., Vanhoutte, P. M., Leung, S. W. S., Suppıan, R., Yusof, M. I., & Rasool, A. H. G. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.01.013 · Cited by 25
Self-citationSellke, N. C., Kuczmarski, A., Lawandy, I. J., Cole, V. L., Ehsan, A., Singh, A. K., Liu, Y., Sellke, F. W., & Feng, J. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.05.090 · Cited by 25
“in arteries and arterioles.(3-8) The mechanism resulting in this microvascular dysfunction is not completely understood, but may be related to an altered response to vasopressin.”
der Werf, R. V., Walter, C., Bietiger, W., Seyfritz, E., Mura, C., Péronet, C., Grandois, J. L., Werner, D., Ennahar, S., Digel, F., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0744-6 · Cited by 25
Mokhtar, S. S., Vanhoutte, P. M., Leung, S. W. S., Yusof, M. I., Sulaiman, W. A. W., Saad, A. Z. M., Suppıan, R., & Rasool, A. H. G. (2013) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.231.217 · Cited by 25
Self-citationZhou, W., Wang, X.-L., Lamping, K. G., & Lee, H.-C. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106666 · Cited by 25
“Endothelial dysfunction with impaired activity of various endothelial-derived factors plays an integral role in diabetic vasculopathy (De Vriese et al., 2000; Brownlee, 2001).”
BackgroundSerglycin in Quiescent and Proliferating Primary Endothelial Cells
Reine, T. M., Vuong, T. T., Rutkovskiy, A., Meen, A. J., Vaage, J., Jenssen, T. G., & Kolset, S. O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145584 · Cited by 26
“Endothelial dysfunction is receiving increasing attention in relation to diabetes [5], cardiovascular disease [6] and cancer [7].”
BackgroundKeita, H., Juan, E. R., Paniagua‐Castro, N., Garduño‐Siciliano, L., & Quevedo, L. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-53 · Cited by 25
Advanced Glycation End Products Acutely Impair Ca2+ Signaling in Bovine Aortic Endothelial Cells
Naser, N., Januszewski, A. S., Brown, B. E., Jenkins, A. J., Hill, M. A., & Murphy, T. V. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00038 · Cited by 25
“…has been demonstrated in a number of experimental, animal models of hyperglycemia and diabetes (Tesfamariam et al., 1991; Fukao et al., 1997; De Vriese et al., 2000; Young et al., 2008; Ding and Triggle, 2010) as well as in clinical studies of both type 1 and type 2 diabetes subjects (McVeigh…”
BackgroundInfluentialLing, X., Cota‐Gomez, A., Flores, N. C., Hernández-Saavedra, D., McCord, J. M., Marecki, J. C., HASKINS, K. M., MCDUFFIE, M. J., Powers, K., Kench, J. A., et al. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.05.027 · Cited by 25
Prothrombotic determinants of coronary atherothrombosis
Ruberg, F. L., & Loscalzo, J. (2002) · Vascular Medicine · doi:10.1191/1358863x02vm448ra · Cited by 25
The vascular endothelium in diabetes: a practical target fordrug treatment?
Andrews, K. L., Pannirselvam, M., Anderson, T. J., Jenkins, A. J., Triggle, C. R., & Hill, M. A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.1.101 · Cited by 25
“Assuming a major role of EDHF in microcirculatory regulation it can be argued that therapeutic targeting to increase its synthesis and/or the use of vascular-bed-specific mimetics of EDHF (or the cellular processes involved) may benefit vascular dysfunction in diabetes and other cardiovascular diseases [28,29].”
BackgroundInfluentialYu, C., Chen, S., Wang, X., Wu, G., Zhang, Y., Fu, C., Hu, C., Liu, Z., Luo, X., Wang, J., et al. (2020) · Microvascular Research · doi:10.1016/j.mvr.2020.104076 · Cited by 24
Metadata
- Authors
- De Vriese, A. S., Verbeuren, T. J., Van de Voorde, J., Lameire, N. H., & Vanhoutte, P. M.
- Affiliations
- Institut Servier (FR)
- Ghent University (BE)
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2000-07
- Volume
- 130
- Issue
- 5
- Pages
- 963-974
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC1572156
- OpenAlex
- W2007880055
- Cited by
- 1,165
- References
- 114
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 32 · 2023: 15 · 2022: 31 · 2021: 27 · 2020: 44 · 2019: 39 · 2018: 41 · 2017: 31 · 2016: 36 · 2015: 50 · 2014: 56 · 2013: 58 · 2012: 62
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- endothelial dysfunction, diabetes mellitus, diabetic vascular disease, endothelium-derived relaxing factor, nitric oxide, prostacyclin, endothelium-derived hyperpolarizing factor, endothelium-dependent vasodilation, protein kinase C, polyol pathway, glycation, oxidative stress, hyperglycemia, ACE inhibitors, folic acid, vascular smooth muscle
- MeSH terms
- Animals, Biological Factors, Diabetes Mellitus, Endothelium, Vascular, Humans, Nitric Oxide, Protein Kinase C, Vasodilation, Signal Transduction, Endothelins, Glycation End Products, Advanced, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.